In addition, univariate and multivariate regression analyses indicated that the high expression of MGST1 was associated with the high clinical stage (TNM), poor primary therapy outcome, poor histological type, high tumor invasion, and poor histologic grade (Yan et al., 2022), hence MGST1 is regarded as a progress predictive factor for endometrial cancer. This evidence concerns the gene MGST1 and endometrial cancer.